Table 4.
Ab reactivity against Ro52 fragments in patients subdivided toanti-Ro52+/anti-Ro60+ and anti-Ro52+/anti-Ro60–.
| Ro52 | SSc Ro52/Ro60+ (n = 15) (%) | SSc Ro52+/Ro60- (n = 28) (%) | p | SjS Ro52/Ro60+ (n = 14) (%) | SjS Ro52/Ro60- (n = 6) (%) | p | SLE Ro52+/Ro60+ (n = 18) (%) | SLE Ro52+/Ro60- (n = 10) (%) | p | DM Ro52+/Ro60+ (n = 3) (%) | DM Ro52+/Ro60- (n = 12) (%) | P | PBC Ro52+/Ro60+ (n = 2) (%) | PBC Ro52+/Ro60- (n = 13) | P |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Full-length Ro52 | 100 | 100 | – | 100 | 100 | – | 100 | 100 | – | 100 | 100 | – | 100 | 100 | – |
| Ro52-1 | 33.3 | 0 | 0.003 | 50.0 | 16.7 | NS | 33.3 | 60.0 | NS | 33.3 | 16.7 | NS | 0 | 7.8 | NS |
| Ro52-2 | 100 | 100 | – | 100 | 100 | – | 100 | 100 | – | 100 | 100 | – | 100 | 100 | – |
| Ro52-3 | 0 | 0 | – | 0 | 0 | – | 0 | 0 | – | 0 | 0 | – | 0 | 0 | – |
| Ro52-4 | 33.3 | 25.0 | NS | 50.0 | 16.7 | NS | 55.6 | 60.0 | NS | 33.3 | 33.3 | NS | 0 | 7.8 | NS |
| Ro52-5 | 60.0 | 57.1 | NS | 71.4 | 33.3 | NS | 55.6 | 60.0 | NS | 33.3 | 41.7 | NS | 50.0 | 38.5 | NS |
SSc, systemic sclerosis; SjS, Sjögren's syndrome; SLE, systemic lupus erythematosus; PBC, primary biliary cholangitis. Significant p-values are indicated in bold.